No Data
No Data
Express News | Intellia Therapeutics Inc - Cash Position Is Expected to Fund Operations Into Late 2026.
Express News | Intellia Therapeutics Inc - on Track to Initiate Phase 3 Study of Ntla-2002 for Treatment of Hereditary Angioedema (Hae) in 2H 2024
Express News | Intellia Therapeutics' Q1 Cash, Cash Equivalents And Marketable Securities Were $953.4M Expected To Provide Cash Runway Into Late 2026
Express News | Intellia Therapeutics Q1 2024 GAAP EPS $(1.12) Beats $(1.39) Estimate, Sales $28.935M Beat $11.504M Estimate
Express News | Intellia Therapeutics Q1 Collaboration Revenue USD 28.935 Million
Express News | Intellia Therapeutics Q1 Operating Expenses USD 142.938 Million